• OncologyTube
    • 0
      • Title
        User LIVE NOW
      • LIVE NOW
        Title
        User
        • Sign In
    • Home
    • Trending

    • Sign In

    • Audios and Videos
    • Videos
    • Audios

    • Channels

    • Browse Channels

    • Categories

    • Acute Lymphoblastic Leukemia 5635
    • Acute Myelogenous Leukemia 148
    • Bladder Cancer 49
    • Bone Metastases 1
    • Brain Cancer 16
    • Breast Cancer 120
    • Business Management 2
    • Cervical Cancer 2
    • Chronic Lymphocytic Leukemia 147
    • Chronic Myelogenous Leukemia 16
    • Colorectal Cancer 75
    • Gastrointestinal Cancer 70
    • General 243
    • Head and Neck Cancers 34
    • Hematologic Malignancies 79
    • Hodgkin Lymphoma 18
    • Immunotherapy 83
    • Kidney Cancer 364
    • Liver Cancer 11
    • Lymphoma 145
    • Melanoma and Skin Cancer 51
    • Multiple Myeloma 332
    • Myeloproliferative Disease 15
    • News 109
    • Non-Hodgkin Lymphoma 43
    • Non-Small Cell Lung Cancer 267
    • Other 110
    • Ovarian Cancer 10
    • Pancreatic Cancer 54
    • Patient Resources 27
    • Prostate Cancer 148
    • Small Cell Lung Cancer 58
    • Soft Tissue Sarcoma 9
    • Supportive Care 38
    • Testicular Cancer 2
    • Urology 6
    • Uterine Cancer 2

    • About
    • Contact
    Carolina Urologic Research Center

    CURC

    My videos
    ProVent Trial: When Will There Be Results?
    0:02:45

    ProVent Trial: When Will There Be Results?

    Neal Shore, MD of Carolina Urologic Research Center @UrologyUS on how the ProVent trial might change the AS treatment landscape.

    ________

    Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, announced early completion of patient enrollment of its Phase 3 ProVent clinical trial. More than 450 subjects were randomized in the large-scale clinical trial, which is evaluating the effectiveness of sipuleucel-T (PROVENGE®) in reducing disease progression in men with early-stage prostate cancer on active surveillance (AS).

    “The rapid pace of enrollment in the ProVent trial is a significant milestone for Dendreon, and underscores a strong interest by patients and physicians in the potential clinical benefit of sipuleucel-T in men on AS,” said Bruce A. Brown, M.D., chief medical officer at Dendreon. “PROVENGE has been proven to extend life in men with mCRPC, and we intend to change the way prostate cancer is treated by showing that immunotherapy can reduce disease progression and the need for aggressive intervention in men with early-stage disease.”

    Nearly 175,000 men are diagnosed with prostate cancer every year.1 Of these, about 30 to 40% with a lower risk of prostate cancer will opt for AS, which includes regular monitoring to assess whether the cancer is progressing, instead of more aggressive treatment options such as surgery or radiation.2,3

    “For men with low-risk, localized prostate cancer, the option of AS is regularly recommended; however, variation in PSA monitoring and the anxiety of having a ‘cancer’ diagnosis causes many men to leave surveillance management and undergo interventional treatment,” said Neal D. Shore, M.D., FACS, ProVent principal investigator, medical director for the Carolina Urologic Research Center and a practicing urologist at Atlantic Urology Clinics in Myrtle Beach, S.C. “Both patients and physicians have desired a proactive therapy for appropriate AS patients in order to optimize their long-term outcomes. Given the numerous studies describing the effectiveness of sipuleucel-T immunotherapy for advanced prostate cancer, we are optimistic that data from ProVent may lead to the first-ever immunotherapy treatment option for men with early-stage prostate cancer.”

    About the ProVent Trial
    The randomized, multicenter Phase 3 ProVent trial is assessing the efficacy of sipuleucel-T in reducing histopathologic disease progression in men on AS. Men age 18 or older who have histologically-proven adenocarcinoma of the prostate diagnosed within 12 months of randomization were eligible to enroll in the study, which is being conducted at approximately 60 sites across the United States. Study participants were randomized 2:1 to receive sipuleucel-T or remain on AS.

    Read here: https://www.oncologytube.com/video/dendreon-completes-phase-3-provent-clinical-trial-evaluation-of-sipuleucel-t-in-active-surveillance-men

    Prostate Cancer
    4 Views
    2 weeks ago
    CURC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    How is Immunotherapy Used in Prostate Cancer? @UrologyUS How is Immunotherapy Used in Prostate Cancer? @UrologyUS
    0:02:42

    How is Immunotherapy Used in Prostate Cancer? @UrologyUS

    Prostate Cancer
    4 Views
    2 weeks ago
    CURC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    ProVent Trial Changing AS Landscape @UrologyUS ProVent Trial Changing AS Landscape @UrologyUS
    0:02:17

    ProVent Trial Changing AS Landscape @UrologyUS

    Prostate Cancer
    4 Views
    2 weeks ago
    CURC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Current Treatment Options in the ProVent Trial Current Treatment Options in the ProVent Trial
    0:04:57

    Current Treatment Options in the ProVent Trial

    Prostate Cancer
    5 Views
    2 weeks ago
    CURC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Phase 3 ProVent Clinical Trial @UrologyUS Phase 3 ProVent Clinical Trial @UrologyUS
    0:08:01

    Phase 3 ProVent Clinical Trial @UrologyUS

    Prostate Cancer
    24 Views
    2 weeks ago
    CURC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login

      Copyright 2019 Medicus Networks, Inc.